Kelli Knight-Brumfield
Family · Franklinton, LANPI 1851741706
Payments from drug & device makers
Across 182 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$726
- Lilly USA, LLC$460
- Novo Nordisk$402
- GSK$129
- Daiichi Sankyo Inc.$121
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$103
- plus $900 from 24 others
What the payments were for
- Food & beverage$2,841100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,841 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $48,583 |
| TrulicityDulaglutide | 27 | $24,973 |
| FarxigaDapagliflozin Propanediol | 41 | $23,149 |
| RybelsusSemaglutide | 20 | $21,491 |
| JardianceEmpagliflozin | 31 | $20,841 |
| MounjaroTirzepatide | 15 | $17,473 |
| JanuviaSitagliptin Phosphate | 27 | $14,736 |
| LinzessLinaclotide | 20 | $12,839 |
| TrintellixVortioxetine Hydrobromide | 19 | $8,874 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,571 |
| Quetiapine Fumarate | 32 | $3,443 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,763 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $2,433 |
| Chlorpromazine Hcl | 12 | $2,340 |
| Gabapentin | 131 | $2,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $402 | $70,07461 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $460 | $42,44642 claims |
| AstraZenecaFarxiga, Symbicort | $63 | $25,91252 claims |
| Boehringer IngelheimJardiance | $34 | $20,84131 claims |
| MerckJanuvia | $14 | $14,73627 claims |
| AbbVieLinzess | $726 | $12,83920 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $98 | $8,87419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in Franklinton
- Savannah MurrayFranklinton$34K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.